MedTrace Logo

Effects of Dynorphin 1-13 on Heroin Addiction - 1

NCT00000244 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-05-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of IV dynorphin in humans during acute heroin abstinence, in order to determine that dynorphin suppresses acute opiate withdrawal, reduces opiate craving, and is safe at doses required to produce the above effects.

Conditions

  • Opioid-Related Disorders
  • Substance Withdrawal Syndrome

Interventions

DRUG

Dynorphin 1 - 13

Sponsors & Collaborators

Principal Investigators

  • Paul Pentel, M.D. · University of Minnesota

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-08-31
Primary Completion
1997-03-31
Completion
1997-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000244 on ClinicalTrials.gov